Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 363

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 363
---
 waiver to sell the shares below $ 2,000.00per share. The Company also issued 807and 992shares of common stock to Keystone as consideration for the ELOC in the three-month period ended September 30, 2024 and the period from February 14, 2024 to September 30, 2024, respectively. The $ 3.6million net proceeds included $ 933,345of issuance costs, including issuances of Common Stock as consideration for the ELOC. On November 8, 2024, the Company consummated a purchase agreement with Keystone (the “November 2024 Keystone Purchase Agreement”) pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $ 20.6million of shares of Common Stock, constituting the remaining unsold balance under the original Keystone Purchase Agreement, subject to certain market conditions. The price of the shares purchased by Keystone under the ELOC is 90% of various volume-weighted average price (“VWAP”) and closing price-based formulae, and requires a waiver, should the selling price be below $ 20.00per share. F-22 On July 11, 2025, the Company entered into an agreement to issue and sell 12,500,000shares of Common Stock under the New Keystone Purchase Agreement. Asthe New Keystone Purchase Agreement constitutes a continuation of the equity line program commenced under the February 2024 Purchase Agreement, the Commitment Shares issued to the Investor pursuant to the February 2024 Purchase Agreement shall satisfy in full the Company’s obligation to deliver any additional shares of Common Stock to the Investor as consideration for entering into the New Keystone Purchase Agreement. During the three months ended March 31, 2025, the Company sold 14,531shares of common stock of the Company for net proceeds of $ 1,227,241under the November 2024 Keystone Purchase Agreement. Additionally, in January 2025, the Company received net proceeds of $ 716,694from the collection of stock subscription receivable, which was reflected as a stock subscription receivable on December 31, 2024. The Company sought and received a waiver to sell the shares below the applicable minimum price in the agreement. During the three months ended June 30, 2025, the Company sold 75,064shares of common stock of the Company for net proceeds of $ 481,971under the November 2024 Keystone Purchase Agreement. During the three months